Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.
Blood. 2022 Apr 14;139(15):2306-2315. doi: 10.1182/blood.2021014738.
Blood. 2022.
PMID: 35167655
Clinical Trial.